eClinical Technology and Industy News

Nobel Prize in Chemistry

Excerpt from the Press Release:

ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), today announced Professor Emmanuelle Charpentier, CRISPR Therapeutics’ co-founder, has been awarded the 2020 Nobel Prize in Chemistry for her groundbreaking work on the CRISPR/Cas9 system. Professor Charpentier co-founded CRISPR Therapeutics together with Rodger Novak and Shaun Foy. She is Founding, Scientific and Managing Director of the Max Planck Unit for the Science of Pathogens and Honorary Professor at Humboldt University, Berlin, Germany. The prize was also awarded to Jennifer Doudna, Professor of Molecular and Cell Biology and Professor of Chemistry at the University of California, Berkeley and Investigator of the Howard Hughes Medical Institute.

“The entire CRISPR Therapeutics team would like to extend our heartfelt congratulations to Professor Emmanuelle Charpentier on becoming a Nobel Laureate,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “Professor Charpentier’s fundamental contribution to the discovery of CRISPR/Cas9 has laid the foundation for our work here at CRISPR Therapeutics, which is focused on developing transformative gene-based medicines with the potential to cure serious human diseases. We are incredibly proud and applaud her for the prestigious recognition she has received for her pioneering work.”

Click the button below to continue reading the Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives